Neuroangiography with iohexol.

R. N. Bryan, S. L. Miller, J. O. Roehm, P. T. Weatherall

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Iohexol is a new, nonionic water-soluble contrast agent undergoing early clinical trials in the United States. Using a double-blind, parallel format, iohexol was compared with meglumine iothalamate (60 patients) for selective cerebral angiography, and with sodium meglumine diatrizoate (40 patients) for arch aortography. Iohexol produced significantly less pain than meglumine iothalamate or sodium meglumine diatrizoate. There were no significant differences in terms of heart rate, blood pressure, or electrocardiogram (ECG) changes. Both produced a transient tachycardia and hypotension after arch aortography, but significantly less so with iohexol. No significant complications occurred. Film quality was comparable between contrast agents except for diminished motion artifacts with iohexol. Iohexol appears to be a superior neuroangiographic contrast agent to current ionic drugs.

Original languageEnglish (US)
Pages (from-to)344-346
Number of pages3
JournalAmerican Journal of Neuroradiology
Volume4
Issue number3
StatePublished - May 1983

Fingerprint

Iohexol
Iothalamate Meglumine
Diatrizoate Meglumine
Contrast Media
Diatrizoate
Aortography
Cerebral Angiography
Tachycardia
Hypotension
Artifacts
Electrocardiography
Heart Rate
Clinical Trials
Blood Pressure
Pain
Water
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Bryan, R. N., Miller, S. L., Roehm, J. O., & Weatherall, P. T. (1983). Neuroangiography with iohexol. American Journal of Neuroradiology, 4(3), 344-346.

Neuroangiography with iohexol. / Bryan, R. N.; Miller, S. L.; Roehm, J. O.; Weatherall, P. T.

In: American Journal of Neuroradiology, Vol. 4, No. 3, 05.1983, p. 344-346.

Research output: Contribution to journalArticle

Bryan, RN, Miller, SL, Roehm, JO & Weatherall, PT 1983, 'Neuroangiography with iohexol.', American Journal of Neuroradiology, vol. 4, no. 3, pp. 344-346.
Bryan RN, Miller SL, Roehm JO, Weatherall PT. Neuroangiography with iohexol. American Journal of Neuroradiology. 1983 May;4(3):344-346.
Bryan, R. N. ; Miller, S. L. ; Roehm, J. O. ; Weatherall, P. T. / Neuroangiography with iohexol. In: American Journal of Neuroradiology. 1983 ; Vol. 4, No. 3. pp. 344-346.
@article{5ded3878d50c481ea72e47c4119ca119,
title = "Neuroangiography with iohexol.",
abstract = "Iohexol is a new, nonionic water-soluble contrast agent undergoing early clinical trials in the United States. Using a double-blind, parallel format, iohexol was compared with meglumine iothalamate (60 patients) for selective cerebral angiography, and with sodium meglumine diatrizoate (40 patients) for arch aortography. Iohexol produced significantly less pain than meglumine iothalamate or sodium meglumine diatrizoate. There were no significant differences in terms of heart rate, blood pressure, or electrocardiogram (ECG) changes. Both produced a transient tachycardia and hypotension after arch aortography, but significantly less so with iohexol. No significant complications occurred. Film quality was comparable between contrast agents except for diminished motion artifacts with iohexol. Iohexol appears to be a superior neuroangiographic contrast agent to current ionic drugs.",
author = "Bryan, {R. N.} and Miller, {S. L.} and Roehm, {J. O.} and Weatherall, {P. T.}",
year = "1983",
month = "5",
language = "English (US)",
volume = "4",
pages = "344--346",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "3",

}

TY - JOUR

T1 - Neuroangiography with iohexol.

AU - Bryan, R. N.

AU - Miller, S. L.

AU - Roehm, J. O.

AU - Weatherall, P. T.

PY - 1983/5

Y1 - 1983/5

N2 - Iohexol is a new, nonionic water-soluble contrast agent undergoing early clinical trials in the United States. Using a double-blind, parallel format, iohexol was compared with meglumine iothalamate (60 patients) for selective cerebral angiography, and with sodium meglumine diatrizoate (40 patients) for arch aortography. Iohexol produced significantly less pain than meglumine iothalamate or sodium meglumine diatrizoate. There were no significant differences in terms of heart rate, blood pressure, or electrocardiogram (ECG) changes. Both produced a transient tachycardia and hypotension after arch aortography, but significantly less so with iohexol. No significant complications occurred. Film quality was comparable between contrast agents except for diminished motion artifacts with iohexol. Iohexol appears to be a superior neuroangiographic contrast agent to current ionic drugs.

AB - Iohexol is a new, nonionic water-soluble contrast agent undergoing early clinical trials in the United States. Using a double-blind, parallel format, iohexol was compared with meglumine iothalamate (60 patients) for selective cerebral angiography, and with sodium meglumine diatrizoate (40 patients) for arch aortography. Iohexol produced significantly less pain than meglumine iothalamate or sodium meglumine diatrizoate. There were no significant differences in terms of heart rate, blood pressure, or electrocardiogram (ECG) changes. Both produced a transient tachycardia and hypotension after arch aortography, but significantly less so with iohexol. No significant complications occurred. Film quality was comparable between contrast agents except for diminished motion artifacts with iohexol. Iohexol appears to be a superior neuroangiographic contrast agent to current ionic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0020759201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020759201&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 344

EP - 346

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 3

ER -